AI-driven Congruence Therapeutics gets $50M to stabilize misfolded proteins By congruence1|2023-01-29T08:53:54-08:0002.09.2022|News|0 Comments Read More
Congruence Therapeutics announces series A financing By congruence1|2023-01-29T08:55:46-08:0002.08.2022|News|0 Comments Read More
Congruence Raises $50 million to Target Rare Diseases of Protein Misfolding By congruence1|2023-01-29T08:57:54-08:0002.08.2022|News|0 Comments Read More
Congruence Therapeutics — The AI platform targeting protein misfolding By congruence1|2023-01-29T08:59:12-08:0002.08.2022|News|0 Comments Read More
Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding By congruence1|2023-01-29T09:01:16-08:0002.08.2022|News|0 Comments Read More
Congruence raises a $50M series A to develop rare disease therapies By congruence1|2023-01-29T09:06:52-08:0002.08.2022|News|0 Comments Read More
Congruence pulls in $50M series A to build a team of ‘drug hunters’ to go after rare disease targets By congruence1|2023-01-29T09:08:10-08:0002.08.2022|News|0 Comments Read More
New OrbiMed-backed biotech aims to replicate Vertex’s wildly successful cystic fibrosis pills in other diseases By congruence1|2023-01-29T09:11:19-08:0002.08.2022|News|0 Comments Read More
Canadian Biotech Leader Clarissa Desjardins Secures $63 Million CAD For Congruence Therapeutics By congruence1|2023-01-29T09:12:41-08:0002.08.2022|News|0 Comments Read More
Montreal biotech startup Congruence raises $50-million to focus on rare disease drugs By congruence1|2023-01-29T09:13:55-08:0002.08.2022|News|0 Comments Read More
